Pay Less, Gain More: STE, RMD Top Abbott Laboratories Stock
This article suggests that investors might find better value and growth in STE and RMD stocks compared to Abbott Laboratories (ABT). It highlights that STE and RMD have lower valuations (P/OpInc) but higher revenue and operating income growth. The analysis uses financial metrics from both the present and one year prior to support the claim that ABT might be overvalued relative to its peers.
Resmed Founder to Receive Prestigious Award
Peter Craig Farrell, founder of ResMed, will receive the 2026 Horatio Alger Award for his accomplishments despite challenges and his commitment to higher education. Farrell founded ResMed in 1989, a global provider of medical devices for sleep apnea, and established the Farrell Family Foundation in 2001. He will be inducted alongside 10 other honorees in Washington, DC, in April.
NEOS Investment Management LLC Has $3.71 Million Stock Position in ResMed Inc. $RMD
NEOS Investment Management LLC significantly increased its stake in ResMed Inc. ($RMD) by 49.1% in Q3, now holding 13,539 shares valued at approximately $3.71 million. This increase is part of a broader trend of institutional investment, with firms like Norges Bank and Vanguard Group Inc. also holding substantial positions, bringing institutional ownership to 54.98%. ResMed recently surpassed quarterly earnings estimates with an EPS of $2.81 and revenue of $1.42 billion, maintaining a "Moderate Buy" consensus rating from analysts with a target price of $299.27.
ResMed Inc. $RMD Shares Sold by BNP PARIBAS ASSET MANAGEMENT Holding S.A.
BNP PARIBAS ASSET MANAGEMENT Holding S.A. reduced its stake in ResMed Inc. ($RMD) by 17.5% in the third quarter, selling 41,123 shares. Despite this, other hedge funds increased their positions, and institutional investors now own 54.98% of the stock. Analysts maintain a "Moderate Buy" rating for ResMed, with a consensus price target of $299.27.
Food Enzymes Market to Witness Massive Growth by 2033 |Novozymes A/S, Dupont de Nemours, Inc., BASF SE
The global food enzymes market is projected to grow significantly, reaching USD 5.53 billion by 2033 from an estimated USD 3.83 billion in 2026, at a CAGR of 5.4%. This growth is driven by rapid innovation and shifting regional dynamics, necessitating strategic insights for decision-makers. The market report provides comprehensive analysis on segmentation, key players like Novozymes A/S and BASF SE, and regional trends.
Danaher to Acquire Masimo in Transaction Valued at $9.9 Billion
Danaher Corporation has entered into a definitive agreement to acquire Masimo Corporation for $180 per share in cash, valuing the transaction at approximately $9.9 billion. Masimo, known for its pulse oximetry and patient monitoring technologies, will operate as a standalone company within Danaher’s Diagnostics segment upon closing. The acquisition is expected to enhance Danaher’s diagnostic capabilities and generate over $530 million in EBITDA for Masimo by 2027.
Cardio Diagnostics Announces Investor Call Amidst Strategic Growth Plans
Cardio Diagnostics Holdings Inc. (CDIO) is holding an investor call to discuss strategic growth initiatives, including advancements in its AI-backed precision cardiovascular test. Despite reporting a net loss of $1.71M, the company maintains a robust 100% gross margin and a low debt-to-equity ratio of 0.03. The call aims to boost investor confidence and align narratives regarding the company's future in the evolving healthcare technology market.
Sleep Aids: Trends, Technologies and Global Markets to 2030 Featuring Key Players Fisher & Paykel Healthcare, ResMed, Philips, Alphabet, Apple and More
The global sleep aid technology market is projected to grow from $103.5 billion in 2025 to $136 billion by 2030, driven by an increase in sleep disorders, advancements in technology, and a rising focus on wellness. Key players like ResMed, Philips, Apple, and Alphabet are leading innovation with a focus on personalized and effective sleep solutions. The market analysis includes segmentation by product type, end-user, sleep disorder, and region, providing a comprehensive overview for stakeholders.
Vanguard Group Inc. Acquires 293,515 Shares of ResMed Inc. $RMD
Vanguard Group Inc. increased its stake in ResMed Inc. by 1.6% in the third quarter, purchasing an additional 293,515 shares to own a total of 19,040,440 shares, valued at approximately $5.21 billion. ResMed reported strong quarterly earnings, beating analyst estimates with an EPS of $2.81 and revenue of $1.42 billion, an 11% increase year-over-year. The company maintains a "Moderate Buy" consensus rating from analysts with an average price target of $299.27, although insiders have recently been net sellers of the stock.
Skandinaviska Enskilda Banken AB publ Has $23.55 Million Stock Holdings in ResMed Inc. $RMD
Skandinaviska Enskilda Banken AB publ recently reduced its stake in ResMed Inc. by 36.6%, selling 49,690 shares but still maintaining holdings worth $23.55 million. Meanwhile, ResMed exceeded quarterly earnings expectations with strong revenue growth and declared a $0.60 quarterly dividend. The company also saw significant insider selling, including shares sold by its CEO, despite analysts maintaining a "Moderate Buy" consensus rating.
Earnings To Watch: iRhythm (IRTC) Reports Q4 Results Tomorrow
iRhythm Technologies (IRTC) is set to report its Q4 results this Thursday after market close. Analysts expect revenue growth of 22.9% year-on-year to $202 million and adjusted earnings of $0.06 per share. The company has a strong history of beating revenue estimates, and its stock is currently trading below the average analyst price target.
West Pharmaceutical clears $1B for stock buybacks and a May dividend
West Pharmaceutical Services (NYSE: WST) has declared a regular quarterly dividend of $0.22 per share, payable on May 6, 2026. Additionally, the company's board has authorized a new $1.0 billion share repurchase program with no expiration date, following the full utilization of its previous program. These actions highlight West's ongoing commitment to returning capital to shareholders through both dividends and buybacks.
22 New 4-Star Stocks This Week
Morningstar identified 22 U.S.-listed stocks that became undervalued, shifting to a 4-star rating, including major companies like IBM and Arista Networks. This analysis is based on Morningstar's proprietary rating system, which considers a stock's price, fair value estimate, and Uncertainty Rating. The overall U.S. market remains moderately undervalued, with 35% of Morningstar-covered stocks considered undervalued.
W.G. Shaheen & Associates DBA Whitney & Co Sells 4,003 Shares of ResMed Inc. $RMD
W.G. Shaheen & Associates DBA Whitney & Co reduced its stake in ResMed Inc. by 7.5%, selling 4,003 shares and now holding 49,528 shares valued at $13.56 million. ResMed reported strong Q3 earnings, beating analyst estimates with EPS of $2.81 and revenue of $1.42 billion, an 11% increase year-over-year. The medical equipment provider also announced a quarterly dividend of $0.60 per share, and Wall Street analysts currently give the stock a "Moderate Buy" rating with an average price target of $299.27.
ResMed Inc. $RMD Shares Sold by ABN Amro Investment Solutions
ABN Amro Investment Solutions significantly reduced its stake in ResMed Inc. by 81.2% in the third quarter, selling 5,427 shares and retaining 1,257 shares valued at $344,000. Despite this, ResMed exceeded Q4 earnings expectations with EPS of $2.81 and revenue of $1.42 billion, also announcing a $0.60 quarterly dividend. While institutional investors generally hold a strong position, recent insider selling activity, including CEO Michael J. Farrell's sale of 4,991 shares, indicates some divestment by executives.
Earnings To Watch: Insulet (PODD) Reports Q4 Results Tomorrow
Insulet Corporation (NASDAQ:PODD) is scheduled to report its Q4 earnings this Wednesday morning, with analysts anticipating a 28.6% year-over-year revenue growth to $768.2 million and adjusted earnings of $1.46 per share. The insulin delivery company has a strong record of exceeding revenue estimates, doing so every quarter for the past two years. Despite recent market underperformance in the healthcare equipment and supplies segment, Insulet's stock trades significantly below its average analyst price target.
Earnings To Watch: Insulet (PODD) Reports Q4 Results Tomorrow
Insulet Corporation (NASDAQ:PODD) is set to report its Q4 earnings on Wednesday morning. Analysts expect revenue growth of 28.6% year-on-year to $768.2 million and adjusted earnings of $1.46 per share. The company has a history of exceeding revenue expectations, and its peers ResMed and DexCom have also reported solid Q4 results, though the healthcare equipment and supplies sector has generally underperformed recently.
Earnings To Watch: Insulet (PODD) Reports Q4 Results Tomorrow
Insulet Corporation (PODD) is set to report its Q4 earnings tomorrow, with analysts expecting a 28.6% year-on-year revenue increase to $768.2 million and adjusted earnings of $1.46 per share. The company has a strong track record of beating revenue estimates, and although the healthcare equipment sector has underperformed recently, Insulet's stock is trading significantly below its average analyst price target.
Aberdeen Group plc Has $75.94 Million Stake in ResMed Inc. $RMD
Aberdeen Group plc reduced its stake in ResMed Inc. (NYSE:RMD) by 6.6% in the third quarter, now holding 276,973 shares valued at $75.94 million. Other institutional investors also adjusted their positions in ResMed, with some increasing and others initiating stakes. The article details ResMed's stock performance, recent earnings, dividend announcement, analyst ratings, and insider trading activity.
ResMed (RMD): Buy, Sell, or Hold Post Q4 Earnings?
ResMed (RMD) shares have underperformed the S&P 500 significantly over the last six months, prompting investors to reevaluate the stock. The company shows positive attributes including consistent currency revenue growth, strong long-term EPS growth, and an increasing free cash flow margin. Despite its recent drawdown, ResMed's stock trades at 21.1x forward P/E, leading to questions about its current buying opportunity.
ResMed (RMD): Buy, Sell, or Hold Post Q4 Earnings?
ResMed's shares (RMD) have underperformed the S&P 500 significantly over the past six months, raising questions for investors. Despite the share price drop, the company exhibits positive attributes including consistent constant currency revenue growth, strong long-term EPS growth, and an increasing free cash flow margin. The article suggests evaluating these factors to determine if the current valuation makes it a good buying opportunity.
ResMed Inc. (RMD) Gains Analyst Confidence as Price Targets Rise on Strong Earnings
ResMed Inc. (RMD) has received increased price targets from KeyBanc Capital Markets and RBC Capital Markets following strong Q2 fiscal 2026 results. Both firms cited strong revenue growth, outperformance in hardware segments (Masks & Accessories, Devices), and improved profitability expectations as reasons for their continued confidence and "Overweight" or "Outperform" ratings. The company's performance, particularly its double-digit growth in revenue and earnings, has bolstered analyst confidence despite underwhelming SaaS figures.
Why is the ResMed share price jumping 7% today?
This article explains why ResMed's share price increased by 7% today.
10 Best Medical Technology Stocks to Invest In
This article highlights STERIS plc (NYSE: STE) as one of the best medical technology stocks to invest in, noting its strong Q3 FY2026 financial results. STERIS exceeded revenue expectations and matched profit forecasts, demonstrating significant year-over-year growth and reaffirming its full-year guidance. The company, which specializes in infection prevention and procedural support, showcased robust organic revenue growth driven by demand across various business lines.
Rhumbline Advisers Boosts Position in ResMed Inc. $RMD
Rhumbline Advisers increased its stake in medical equipment provider ResMed Inc. by 3.8% in the third quarter, now owning 318,937 shares worth $87.3 million. Several other institutional investors also modified their holdings, with 54.98% of ResMed stock currently held by institutional investors. ResMed's stock recently traded at $245.93, has a market cap of $35.83 billion, and announced a quarterly dividend of $0.60 per share.
Envestnet Asset Management Inc. Raises Holdings in ResMed Inc. $RMD
Envestnet Asset Management Inc. increased its stake in ResMed Inc. (NYSE:RMD) by 10.4% in Q3, bringing its total holdings to 99,233 shares valued at approximately $27.16 million. ResMed exceeded Q3 earnings and revenue expectations, reporting an EPS of $2.81 on revenues of $1.42 billion, and maintains a "Moderate Buy" consensus rating with a $299.27 target price. The company also declared a quarterly dividend of $0.60 per share, yielding nearly 1.0%.
Is Waters a Better Buy Than Thermo Fisher Scientific?
This article analyzes whether Waters (WAT) is a better investment than Thermo Fisher Scientific (TMO). It suggests that WAT offers superior revenue growth, better profitability, and a relatively lower valuation compared to TMO, despite TMO's recent stock decline. The comparison is supported by side-by-side financial metrics and historical market performance data for both companies.
CPAP Headgear Market to See Thriving Worldwide | ResMed • Philips Respironics • Fisher & Paykel Healthcare
Coherent Market Insights has published a report on the CPAP Headgear Market, forecasting its growth from 2026 to 2033. The report provides a thorough analysis of market trends, competition, geographic distribution, and growth potential, including performance factors, risk assessment, and projected ROI. It emphasizes the market's influence on the global economy through technological advancements and sustainability efforts, identifying key players like ResMed and Philips Respironics.
ResMed Tests Smart CPAP Pressure Tool in New Sleep Apnea Trial
ResMed (RMD) is conducting a new clinical trial to test a software tool, the APAP Pressure Match tool, designed to improve CPAP pressure settings for sleep apnea patients. This tool uses personalized data to fine-tune pressure ranges, aiming to be as effective as standard methods while simplifying treatment setup for clinicians. The trial, currently in the setup phase and not yet recruiting, signifies ResMed's focus on software-driven personalization in sleep and respiratory care, which could enhance adoption and pricing power if successful.
3 Quality Compounders to Consider Right Now
The article highlights three "quality compounders" – Comfort Systems (FIX), ResMed (RMD), and Amphenol (APH) – explaining why their business models, competitive advantages, and financial performance make them attractive investments. It details their market capitalization, growth metrics like revenue and EPS, and forward P/E ratios, suggesting they could turbocharge returns. The article also mentions that further analysis is available in free research reports for each company.
Baader Bank Aktiengesellschaft Sells 8,794 Shares of ResMed Inc. $RMD
Baader Bank Aktiengesellschaft significantly reduced its stake in ResMed Inc. by selling 8,794 shares, lowering its holdings to 10,417 shares valued at $2.82 million. This comes as ResMed outperformed quarterly expectations with strong EPS and revenue growth, and analysts maintain a "Moderate Buy" rating with a consensus target price of $299.27. Despite institutional buying, company insiders have recently sold over $4.6 million in shares.
Michael Farrell Sells 4,991 Shares of ResMed (NYSE:RMD) Stock
Michael Farrell, CEO of ResMed (NYSE:RMD), sold 4,991 shares of the company's stock on February 9th, 2026, for a total value of $1,366,435.98 at an average price of $273.78 per share. Following this transaction, Farrell's direct ownership in the company decreased by 1.06%, now totaling 466,223 shares valued at over $127 million. The article also provides an overview of ResMed's financial performance, stock metrics, recent dividend announcement, institutional ownership changes, and analyst ratings.
Zacks.com featured highlights include Amphenol, GE Aerospace, ResMed and Ameriprise Financial
This article highlights four Growth at a Reasonable Price (GARP) stocks: Amphenol, GE Aerospace, ResMed, and Ameriprise Financial, recommended by Zacks Investment Research for their potential to offer significant returns. The GARP strategy combines elements of value and growth investing, targeting undervalued stocks with strong prospects and stable growth rates. Each company's recent performance, strategic initiatives, and analyst outlook are discussed to demonstrate their alignment with GARP metrics.
The Truth About ResMed Inc (NYSE - replacing with ROST): Why Everyone Is Suddenly Watching This Stoc
This article discusses the recent market interest in ResMed Inc (RMD) and Ross Stores (ROST), analyzing whether they represent genuine investment opportunities or are simply passing hype. It compares the two companies' business models—ResMed in sleep and respiratory tech versus Ross Stores in off-price retail—and evaluates their stock performance, market perception, and suitability for different types of investors. The author emphasizes the importance of fundamental analysis over social media buzz for long-term investment decisions.
Zacks.com featured highlights include Amphenol, GE Aerospace, ResMed and Ameriprise Financial
This article from Zacks.com highlights four "Growth at a Reasonable Price" (GARP) stocks: Amphenol (APH), GE Aerospace (GE), ResMed (RMD), and Ameriprise Financial (AMP). It explains the GARP investment strategy, which combines elements of both growth and value investing, seeking undervalued stocks with strong future prospects. The article provides detailed business updates and financial outlooks for each of the featured companies, citing recent performance, strategic initiatives, and analyst consensus estimates.
With 73% ownership in ResMed Inc. (NYSE:RMD), institutional investors have a lot riding on the business
Institutional investors hold a significant 73% ownership stake in ResMed Inc. (NYSE:RMD), making the company's stock price highly sensitive to their trading decisions. Major shareholders include The Vanguard Group, Inc. (14%), BlackRock, Inc. (8.5%), and State Street Global Advisors, Inc. (4.6%), with these institutions collectively holding a substantial, though not full, majority. While insider ownership is less than 1%, the general public holds about 26% of the company's shares.
Respiratory Health For Patients
Baxter is committed to helping patients with respiratory conditions breathe easier through innovative products and support services. Their offerings include the Monarch Airway Clearance System, which utilizes High Frequency Chest Wall Oscillation (HFCWO) therapy to clear airways, and the CARE Connex Program for comprehensive patient assistance. The company focuses on enabling patients to live their best lives with fewer limitations, regardless of whether their condition requires short-term or ongoing therapy.
Stifel reiterates Buy rating on Erasca stock, maintains $10 price target By Investing.com
Stifel has reiterated its Buy rating and $10 price target for Erasca Inc. (NASDAQ:ERAS) after a fireside chat with the company's CFO/CBO. Despite the stock trading above its price target and showing significant recent returns, the company remains unprofitable with a net income of -$127.69 million, though it has a strong balance sheet. Erasca's ERAS-0015 drug candidate is viewed as having a competitive advantage in the panRAS landscape, and the company recently completed a public offering to raise substantial gross proceeds.
Home Depot Stock At $385: Is It a Value Trap in 2026?
Home Depot's stock is currently priced at $385, with a modeled target of $438 by 2028, implying a 14% upside. However, a valuation model suggests only a 6.8% annualized return over two years, which is below typical equity risk thresholds and thus warrants a "Sell" recommendation for investors seeking higher returns. The model's assumptions include 4.2% revenue growth, 13% operating margins, and a 24x exit multiple, indicating that the stock may not offer sufficient compensation for market risks.
Why You Might Be Interested In ResMed Inc. (NYSE:RMD) For Its Upcoming Dividend
ResMed Inc. (NYSE:RMD) is set to pay a dividend of US$0.60 per share, with an ex-dividend date in the next four days. The company demonstrates strong dividend sustainability, with a low payout ratio of 22% of its income and 19% of its free cash flow. ResMed has also shown consistent earnings per share growth of 19% annually over the last five years and a 7.9% dividend growth rate over the past decade, suggesting a business that is reinvesting for growth while rewarding shareholders.
Resmed director Farrell sells $502k in stock
ResMed director Peter C. Farrell sold 2,000 shares of company stock for $502,620 on February 4, 2026, at a price of $251.31 per share. Since the sale, ResMed shares have risen to $271.56, indicating an 8.1% premium. The company, a medical equipment manufacturer, has a market capitalization of $39.57 billion and a P/E ratio of 26.81, and offers a 0.9% dividend yield, having maintained payments for 15 consecutive years.
Resmed director Farrell sells $502k in stock By Investing.com
ResMed director Peter C. Farrell sold 2,000 shares of company stock worth $502,620 on February 4, 2026, under a pre-arranged trading plan. Despite the sale, ResMed shares have since risen, and the company maintains a strong financial health score with a consistent dividend payment history. Recent Q2 FY26 earnings exceeded analyst expectations, leading to several price target increases from firms like RBC Capital and KeyBanc.
Resmed: global general counsel Rider sells $13,000 in stock
ResMed Inc.'s Global General Counsel, Rider Michael J, sold 50 shares of the company's common stock for $13,000 on February 4, 2026, under a Rule 10b5-1 plan. Despite this insider sale, analysts maintain a positive outlook on ResMed following its strong Q2 fiscal 2026 performance, where it exceeded EPS forecasts and matched revenue expectations. The stock is currently trading slightly below its Fair Value estimate according to InvestingPro analysis.
ResMed (NYSE:RMD) General Counsel Sells $13,000.00 in Stock
ResMed's General Counsel, Michael Rider, sold 50 shares of RMD stock for $13,000 on February 4th, reducing his total holdings by 0.51%. This transaction follows strong Q2 earnings that surpassed expectations, with the company reporting increased revenue and EPS. ResMed also announced a quarterly dividend of $0.60 per share, payable in March.
ResMed (NYSE:RMD) Director Sells $502,620.00 in Stock
ResMed (NYSE:RMD) Director Peter Farrell sold 2,000 shares of the company stock worth $502,620 on February 4th, reducing his stake by 3% to 64,773 shares. This transaction follows a strong quarter for ResMed, where it exceeded EPS estimates and reported an 11% year-over-year revenue increase. The company also declared a quarterly dividend of $0.60 and maintains a "Moderate Buy" consensus rating from analysts with an average target price of $299.27.
Smart Sand, Inc. Achieves 140.93% Return, Outperforming NetApp and ResMed
Smart Sand, Inc., a Micro Cap company in the Building Products sector, has shown a significant return of 140.93% over the past six months. This performance starkly contrasts with NetApp, Inc. (IT - Hardware) and ResMed, Inc. (Pharmaceuticals & Biotechnology), both Mid Cap companies, which experienced declines of -3.53% and -6.3% respectively. The article highlights Smart Sand's success against the challenges faced by its larger counterparts in different industries.
RMD Stock Up Following Q2 Earnings & Revenue Beat, Margins Expand
Resmed Inc. (RMD) reported strong second-quarter fiscal 2026 results, with adjusted EPS increasing 15.6% year over year to $2.81, beating the Zacks Consensus Estimate. Revenues also surpassed expectations, rising 11% to $1.42 billion, driven by growth in both Sleep and Breathing Health and Residential Care Software segments. The company demonstrated significant margin expansion, with adjusted gross margin up 340 basis points to 62.6% and adjusted operating margin expanding 263 basis points to 36.6%.
ResMed Inc (RMD) Stock Price Down 0% on Feb 5
Shares of ResMed Inc (RMD) experienced a 0.00% dip in mid-day trading on February 5th, with the stock closing at $263.03. This places RMD 10.48% below its 52-week high but 31.57% above its 52-week low. Wall Street analysts provide an average price target of $297.49, implying a 13.10% upside, and the stock currently holds an "Outperform" recommendation from brokerage firms.
ALGN Stock Climbs on Q4 Earnings and Revenue Beat, Margins Down
Align Technology (ALGN) reported better-than-expected Q4 2025 earnings and revenue, with adjusted EPS up 34.8% year-over-year and total revenue increasing by 5.3%. Despite these gains, the company's gross and operating margins contracted, attributed to increased costs and expenses. ALGN's stock rose significantly in after-hours trading following the announcement, and the company issued a positive outlook for full-year 2026 revenue growth.
The Top 5 Analyst Questions From ResMed's Q4 Earnings Call
ResMed's Q4 performance exceeded expectations due to strong demand for masks and devices, growth in digital health software, and operational efficiencies. CEO Michael Farrell highlighted double-digit growth in the U.S. mask segment and increased patient engagement, including those using GLP-1 medications. This article details the top five analyst questions from the earnings call, covering topics like the contribution of VirtuOx, the impact of GLP-1 drugs, SG&A expenses, patient funnel improvements, and competitive dynamics.
